Saitoh Akihiko, Singh Kumud K, Sandall Sharsti, Powell Christine A, Fenton Terrence, Fletcher Courtney V, Hsia Karen, Spector Stephen A
Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla 92093-0672, USA.
J Allergy Clin Immunol. 2006 Apr;117(4):909-15. doi: 10.1016/j.jaci.2006.01.013.
In a cohort of children receiving highly active antiretroviral therapy (HAART) with sustained plasma HIV-1 RNA < 50 copies/mL, children who reached undetectable RNA after week 8 (slow responders, median: week 20) had higher HIV-1 intracellular DNA (HIV-1 DNA) and equal or greater CD4+ T-lymphocyte counts compared with children who reached undetectable plasma HIV-1 RNA by week 8 (rapid responders) throughout HAART.
To determine whether levels of T-cell receptor excision circles (TRECs) could explain the apparent inconsistency between the quantity of HIV-1 DNA and CD4+ T-lymphocyte counts in HIV-1-infected children receiving HAART with sustained virologic suppression.
T-cell receptor excision circles and HIV-1 DNA and plasma HIV-1 RNA were quantified longitudinally by PCR in 31 children (median age, 5.6 years) with sustained undetectable plasma HIV-1 RNA for >104 weeks of HAART.
There was a positive correlation between TREC and HIV-1 DNA during HAART, notably at weeks 48 and 80 (P < .004). During the early stage of HAART, TREC levels positively correlated with CD4+ T-lymphocyte percentages (P < .02) and naive CD4+ T-lymphocyte counts (P < .001) and percentages (P = .05). Median TREC levels were consistently equal or higher in slow responders compared with rapid responders (P < .001) despite slow responders having consistently greater quantities of HIV-1 DNA.
To maintain adequate levels of CD4+ T-lymphocytes, children with high HIV-1 DNA maintain high levels of TREC while receiving HAART. Thus, a thymic control mechanism is required to maintain new CD4+ T lymphocytes in the presence of persistent virus.
The TREC level is a useful marker of thymic function in HIV-infected children.
在一组接受高效抗逆转录病毒疗法(HAART)且血浆HIV-1 RNA持续低于50拷贝/毫升的儿童中,与在第8周前血浆HIV-1 RNA达到检测不到水平(快速反应者)的儿童相比,在第8周后达到RNA检测不到水平(反应缓慢者,中位数:第20周)的儿童在整个HAART治疗期间HIV-1细胞内DNA(HIV-1 DNA)水平更高,且CD4 + T淋巴细胞计数相等或更高。
确定T细胞受体切除环(TREC)水平是否可以解释在接受HAART并实现病毒学持续抑制的HIV-1感染儿童中,HIV-1 DNA数量与CD4 + T淋巴细胞计数之间明显的不一致。
通过PCR对31名(中位年龄5.6岁)接受HAART超过104周且血浆HIV-1 RNA持续检测不到的儿童的T细胞受体切除环、HIV-1 DNA和血浆HIV-1 RNA进行纵向定量。
在HAART治疗期间,TREC与HIV-1 DNA之间存在正相关,尤其是在第48周和第80周(P <.004)。在HAART治疗的早期阶段,TREC水平与CD4 + T淋巴细胞百分比(P <.02)、初始CD4 + T淋巴细胞计数(P <.001)和百分比(P =.05)呈正相关。尽管反应缓慢者的HIV-1 DNA数量始终较多,但反应缓慢者的TREC中位水平始终等于或高于快速反应者(P <.001)。
为维持足够水平的CD4 + T淋巴细胞,HIV-1 DNA水平高的儿童在接受HAART治疗时会维持较高水平的TREC。因此,在存在持续病毒的情况下,需要一种胸腺控制机制来维持新的CD4 + T淋巴细胞。
TREC水平是HIV感染儿童胸腺功能的有用标志物。